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Abstract The objective of this study was to investigate
whether metabolic tumor volume (MTV) by positron emis-
sion tomography (PET) can be a potential prognostic tool
when compared with Ann Arbor stage, in stages II and III
nodal diffuse large B cell lymphoma (DLBCL). We evaluated
169 patients with nodal stages II and III DLBCL who
underwent measurements with PET prior to rituximab
combined with cyclophosphamide, adriamycin, vincristine,
and prednisone (R-CHOP). Cutoff point of MTV was
measured using the receiver operating characteristic (ROC)
curve. During a median period of 36 months, stage II was
59.2% and III was 40.8%. Using the ROC curve, the MTVof
220 cm
3 was the cutoff value. The low MTV group
(<220 cm
3) had longer progression-free survival (PFS) and
overall survival (OS), compared with the high MTV group
(≥220 cm
3)( p<0.001,p<0.001). Stage II patients had longer
survival than those in stage III (PFS, p=0.011; OS, p=
0.001). The high MTV group had lower PFS and OS
patterns, regardless of stage, compared with the low MTV
group (p<0.001,p<0.001). Multivariate analysis revealed an
association of the high MTV group with lower PFS and OS
(PFS, hazard ratio (HR)=5.300, p<0.001; OS, HR=
7.009, p<0.001), but not stage III (PFS, p=0.187; OS, p=
0.054). Assessment of MTV by PET had more potential
predictive power than Ann Arbor stage in the patients that
received R-CHOP.
Keywords Diffuse large B cell lymphoma.Positron
emission tomography.Rituximab
Introduction
Introduction of rituximab combined with cyclophospha-
mide, adriamycin, vincristine, and prednisone (R-CHOP)
has resulted in improved survival outcomes in patients with
diffuse large B cell lymphoma (DLBCL) [1–8]. DLBCL is
a heterogenous group of B cell non-Hodgkin lymphoma
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DOI 10.1007/s00277-011-1357-2(NHL), rather than a single clinicopathologic entity [9].
Multiple histologic subtypes were recognized and several
molecular and genetic abnormalities were variably present.
In recent years, most studies have focused on identifying
molecular markers in order to define new prognostic factors.
However, no relevant prognostic molecular markers have
been validated, and an agreement on prognostic models has
not yet been reached [10].
Aggressive NHL, including DLBCL, has been staged
according to the Ann Arbor staging system, which was
originally designed for Hodgkin lymphoma (HL). The
International Prognostic Index (IPI) is the primary clinical
tool used to predict the outcome for patients with aggressive
NHL based on the number of negative prognostic factors at
the time of diagnosis, including Ann Arbor stage III/IV and
other factors (age≥60 years, elevated lactate dehydrogenase
level, Eastern Cooperative Oncology Group performance
status ≥2, more than one extranodal site) [11]. However, due
to the higher heterogeneity and hematogenous spread pattern
of dissemination in NHL relative to contiguous lymphatic
spread with HL, Ann Arbor staging system has limited value
in the context of assessing accurate tumor burden in NHL.
For instance, despite the presence of a high tumor burden in
stage II disease, the IPI score can be “zero point,” whereas
the score can be “one point” in stage III disease even if the
tumor burden is low.
New imaging techniques such as 18F-fluorodeoxyglucose
(
18F-FDG) positron emission tomography (PET) have been
used as prognostic tools in NHL [12, 13]. As indicated by
several positive sets of data, imaging techniques have
become an important tool in clinical decisions on therapeutic
strategies for treating aggressive NHL, including DLBCL
[14–16]. The objective of the present study was to
investigate whether metabolic tumor volume (MTV) by
PET can be used as a potential prognostic tool, compared
with the Ann Arbor stage, in patients with stages II and III
nodal DLBCL.
Materials and methods
One hundred sixty-nine patients with de novo nodal
DLBCL between July 2004 and November 2008 in five
medical centers (Pusan National University Hospital,
Dong-A University Medical Center, Kosin University
Gospel Hospital, Busan Paik Hospital, and Gyeongsang
National University Hospital) who underwent PET–CT at
diagnosis were enrolled in the present study. All patients
received six to eight cycles of R-CHOP therapy accord-
ing to Coiffier et al [1]. The median follow-up duration
was 36 months, and the male-to-female ratio was 1.56:1
(Table 1).
Table 1 The baseline characteristics and comparison between stages II and III nodal DLBCL patients
Total (n=169) (%) Stage II (n=100) (%) Stage III (n=69) (%) p value
Age, median, years (range) 61.0 (21–79) 62 (22–79) 59 (21–76) 0.327
Sex, male/female 103/66 63/37 40/29 0.511
Disease status
Age≥60 years 98 (60.0) 63 (63.0) 35 (50.7) 0.113
Elevated LDH 77 (45.6) 43 (43.0) 34 (49.3) 0.422
ECOG at least 2 42 (24.9) 21 (21.0) 21 (30.4) 0.164
B symptoms 71 (42.0) 37 (37.0) 34 (49.3) 0.113
Bulky LN (≥5 cm) 7 (4.1) 3 (3.0) 4 (5.8) 0.911
MTV, median, cm
3 (range) 198.1 (4.5–1,990.7) 122.1 (4.5–1,251.1) 434.3 (10.1–1,990.7) <0.001
IPI score, n (%) 0.070
0–2 125 (73.9) 78 (78.0) 47 (68.1)
3–4 44 (26.1) 22 (22.0) 22 (31.8)
Response by revised IWC
CR 142 (84.0) 87 (87.0) 61 (88.4) 0.786
PR 21 (12.4) 13 (13.0) 5 (7.2) 0.236
SD 6 (3.6) 0 (0.0) 3 (4.3) 0.036
Survival (%)
3-year PFS 73.4 80.0 63.8 0.011
3-year OS 76.3 85.0 64.2 0.001
LDH lactate dehydrogenase, ECOG Eastern Cooperative Oncology Group, MTV metabolic tumor volume, IPI international prognostic index, PFS
progression-free survival, OS overall survival
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Patients were included if they had primary nodal localization
as a de novo DLBCL histotype, and the stage was II or III
according to Ann Arbor staging and had been available for
clinical follow-up. Patients were excluded if they presented
any extranodal involved site, DLBCL secondary to low-grade
NHL, or other treatment, including radiotherapy after R-
CHOP therapy or autologous stem cell transplantation and if
there was a discrepancy in the LNs between PET and
conventional computed tomography (CT). In addition,
patients were excluded if they had uncontrolled diabetes
mellitus, evidence of infection at the time of diagnosis,
especially active tuberculosis, or antibodies against human
immunodeficiency virus.
Measurement of MTV by PET/CT
Dual-modality PET/CT tomography was performed on a
biograph (Siemens Medical Solution, Hoffman Estates, IL,
USA), based on a dual-slice helical CT and a full-ring PET
tomography. FDG-PET images were evaluated for regions of
focally increased tracer uptake. In the target lesions of FDG
tracer uptake,SUVof ≥2.5ascontouringborder wasconsidered
torepresentlymphoma,assuggestedbyFreudenbergetal.[17].
The CT images were used for PET attenuation correction.
Imaging reconstruction of corrected emission data was
performed after Fourier transform with AWOSEM software
(two iterations, eight subsets, 5 mm Gaussian filter). The CT
criterion for pathologic LN was that the LN exceeded 1.0 cm
in all regions, except the groin. PET image also evaluated the
area of focal tracer uptake; thus, the SUV of ≥2.5 was
considered as pathologic LN, and the MTV was measured
afterCTattenuationcorrection.CTimageswereacquiredwith
130 mAs, 130 kV, and slice width (or 5 min and table feed) of
8 mm per rotation. Intravenous or oral contrast agents were
used in all patients, and a standardized breathing protocol was
applied.PETimageswereinterpretedbynuclear physiciansat
each institution. Data were then reviewed by two nuclear
medicine experts at Pusan National University Hospital.
Pretreatment and response evaluation
Pretreatment staging and response evaluation after six or eight
cyclesofR-CHOPtherapywerebasedonclinicalexamination,
CTscan of the neck, chest, abdomen, and pelvis, bone marrow
biopsy, and PET/CT. Response was assessed according to
revised International Workshop Criteria [14]. Criteria were as
follows: complete response (CR) is defined as (a) no signs or
symptoms of disease, (b) negative PET and regression to
normal size on CT, and (c) normal bone marrow. Partial
response (PR) is defined as 50% decrease in tumor size but
with a positive PET at the prior disease site. Stable disease
(SD) is defined as (a) positive PET at the prior sites of disease
and no new sites on CT or PET and (b) PET negative and no
change in size of previous lesions on CT. Progressive disease
is defined as (a) appearance of a new lesion >1.5 cm in any
axis, ≥50% increase in the sum of the product of the
diameters of more than one node, or ≥50% increase in the
longest diameter of a previously identified node>1 cm in
short axis and (b) lesions PET positive if FDG-avid
lymphoma or PET positive prior to therapy.
Statistical analyses
The Mann–Whitney U test was used for assessment of
differences in the frequency-independent prognostic factors of
stages II and III groups. Progression-free survival (PFS) was
calculated from the date of diagnosis to documented disease
progression; observations were censored on the date the
patient was last known to be alive or, for patients dying as a
result of causes unrelated to lymphoma or treatment, the date
of death. Overall survival (OS) was calculated from the date
of diagnosis until death as a result of any cause or the date
last known to be alive. PFS and OS were estimated by the
Kaplan–Meier method, and the difference was compared
using a log-rank test. Receiver operating characteristic (ROC)
curve was performed for estimation of the accuracy in
prediction of ideal cutoff value of MTV. Estimation of
sensitivity and specificity was based on the cutoff value of
MTV. SPSS software for Macintosh (SPSS 15.0; Chicago, IL,
USA) was used for statistical data processing. A probability
value <0.05 was considered statistically significant.
Results
Patient characteristics
One hundred sixty-nine patients with stage II/III nodal
DLBCL were treated with R-CHOP from 2004 to 2008,
and the baseline characteristics were summarized in Table 1.
Differences of several independent prognostic factors
between stages II and III groups were not observed.
However, MTVs in the stage III group were larger when
compared with the stage II group (p<0.001). CR and PR of
the treatment response were comparable between the two
groups (p=0.786, p=0.236, respectively), whereas SD was
higher in the stage III group when compared with the
stage II group (p=0.036, Table 1).
Measurement of cutoff value of MTV in patients
at diagnosis
ROC curve analysis was employed to calculate the accuracy
oftheidealcutoffvalue,whichwasusedtodistinguishthelow
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under the ROC curve was 0.857 (p<0.001; 95% conference
interval, 0.782–0.932), which suggests that the value was
important to prediction of survival. Various cutoff values of
MTV were used to obtain a reasonable balance of sensitivity
and specificity; 220 cm
3 of various values acquired a
sensitivity of 91.7% and specificity of 65.3% (Fig. 1).
Clinical outcome according to stage or MTV
Three-year PFS and OS were significantly higher in the stage
II group than in the stage III group (PFS, 80.0% in stage II
versus63.8% instage III,p=0.011; OS, 85.0% in the stage II
group versus 64.2% in stage III, p=0.001, Table 1). Clinical
outcome according to the low MTV group versus the high
MTV group was also analyzed, and the results were shown
in Fig. 2a, b. PFS and OS were significantly higher in the
low MTV group than in the high MTV group (PFS 89.8%
versus 55.6%, p<0.001; OS 93.2% versus 58.0%, p<0.001).
Clinical outcome according to stage combined with MTV
Further analysis was performed to determine whether tumor
burden was of clinical importance between stages II and III
Fig. 1 Receiver operating characteristic curve analysis in survival
prediction according to MTV in 160 stages II and III nodal DLBCL
patients (continuousvariable). Areaunder thecurvewas 0.857 (p<0.001,
95% CI 0.782–0.932), and 220 cm
3 was determined as the cutoff value
of MTV for comparison. Sensitivity and specificity of the dichotomized
MTV (≥220 versus <220) were 91.7% and 65.3%, respectively
Fig. 2 Comparisons of survival according to the cutoff value of MTV
and stage combined with the cutoff value of MTV. a PFS and b OS
according to the cutoff value of MTV were higher in the low MTV
group compared with the high MTV group (PFS <0.001; OS, p<0.001,
respectively). c PFS and d OS of stages II and III with the low MTV
groups were higher compared with other groups, whereas survival
between the two low MTV groups (PFS 90.5% in stage II versus 88.0%
in stage III, p=0.703; OS 95.2% in stage II versus 88.0% in stage
III, p=0.268) or high MTV groups (PFS 60.5% in stage II versus
51.2% in stage III, p=0.347; OS 65.8% in stage II versus 51.2% in
stage III, p=0.175) were not different
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foursubgroupsbasedontumorburdenandstageIIorIII(stage
II group with low MTV, stage II group with high MTV, stage
III group with low MTV, and stage III group with high MTV).
The high MTV group, regardless of stage, had lower PFS and
OS patterns, compared with the low MTV group (PFS and OS
in stage II with low MTV, 90.5% and 95.2%; in stage III with
lowMTV,88.0%and88.0%versusinstageIIwithhighMTV,
60.5% and 65.8%; in stage III with high MTV, 51.2% and
51.2%; p<0.001, p<0.001), whereas the prognostic impact
of stage in the same MTV group was absent (in the low MTV
group,difference ofPFSand OSaccording tostage, p=0.703,
p=0.268; in the high MTV, p=0.347, p=0.175, Fig. 2c, d).
Univariate and multivariate analysis
In the univariate analysis, stage III was still a poor prognostic
factor for PFS and OS (PFS, hazard ratio (HR)=2.094, 95%
confidence interval (CI)=1.162–3.773, p=0.014; OS, HR=
2.758, 95% CI=1.454–5.234, p=0.002). In addition, high
MTV was also shown to be a predictive parameter for poor
survival (PFS, HR=5.799, 95% CI=2.787–12.055, p<0.001;
OS, HR=8.097, 95% CI=3.395–19.309, p<0.001, Table 2).
To further investigate the prognostic value of high MTV,
multivariate analysis using a Cox proportional hazard model
was performed on the high MTV and stage III groups. This
analysis showed that high MTV was an independent factor
forthepredictionofanunfavorableoutcome(PFS,HR=5.300,
95% CI=2.517–11.162, p<0.001; OS, HR=7.009, 95% CI=
2.902–16.927, p<0.001), whereas stage III had no significant
value (PFS, HR=1.496, 95% CI=0.822–2.724, p=0.187; OS,
HR=1.894, 95% CI=0.988–3.628, p=0.0.054, Table 3).
Discussion
Since its publication in 1971, Ann Arbor staging has been
used as the staging system for both HL and NHL lymphomas
[15]. However, the number of involved nodal sites was not
considered in this optional staging system. For these reasons,
the Ann Arbor scheme was revised, and modifications in the
staging procedures were recommended within the framework
of the Ann Arbor Classification by a committee meeting in
the Cotswolds under the auspices of the Cancer Research
Campaign and Imperial Cancer Research Fund [16]. How-
ever, accurate tumor burden was also not considered in the
staging system. Interestingly, one previous study demon-
strated that tumor burdens could be discriminated (i.e., low
tumor burden vs. high burden) based on the number of
extensive nodal areas and extranodal sites [18]. The author of
this study suggested that tumor burden measured by their
method was an excellent prognostic factor in CHOP era.
However, this method only involved a simple arithmetic
system, and no imaging techniques were utilized. Because
accurate tumor surveillance is a fundamental precondition for
assessment of prognosis and therapeutic options in patients
with NHL, a more accurate staging system model should be
developed, especially in the era of rituximab.
Arecentmeta-analysisstudy,basedondatafromthreelarge
clinical trials, suggested that treatment with rituximab resulted
in significant improvement of the treatment outcome within
eachof thefourIPI factors,includingAnnArborstage[19]. Of
particular interest, the study revealed data from the MabThera
International Trial, where the advanced stage (III/IV) was no
longer an independent factor of OS in multivariate analysis.
In this study, data from the MegaCHOEP Trial also
demonstrated that the advanced stage showed borderline
correlations with PFS and was not associated with OS. In
addition, data from the RICOVER-60 trial shown in this
study demonstrated that the advanced stage was not an
independent factor of PFS and OS. These findings indicate
that treatment with rituximab resulted in improved outcome
of advanced stage patients and diminished gap of survival
between the limited stage and advanced stage according to
the Ann Arbor staging system. For these reasons, we do not
believe that the advanced stage itself would be a true poor
Table 2 Univariate analysis for
prognostic factors in patients
MTV metabolic tumor volume
Prognostic factors Progression-free survival Overall survival
HR (95% CI) p value HR (95% CI) p value
Stage III 2.094 (1.162–3.773) 0.014 2.758 (1.454–5.234) 0.002
High MTV 5.797 (2.787–12.055) <0.001 8.097 (3.395–19.309) <0.001
Table 3 Multivariate analysis
for prognostic factors in patients
MTV metabolic tumor volume
Prognostic factors Progression-free survival Overall survival
HR (95% CI) p value HR (95% CI) p value
Stage III 1.496 (0.822–2.724) 0.187 1.894 (0.988–3.628) 0.054
High MTV 5.300 (2.517–11.162) <0.001 7.009 (2.902–16.927) <0.001
Ann Hematol (2012) 91:697–703 701prognostic factor in the era of rituximab. According to the
results of meta-analysis in the above clinical trial, the
authors demonstrated that four IPI factors were independent
factors. However, it did not address several discrepancies,
including patient characteristics, using regimens other




has resulted in increased diagnostic accuracy and allowed
clinicians to distinguish primary malignant lesions from
benign areas. Thus,
18F-FDG-PET has been reported to
provide superior information on staging of NHL when
compared with conventional CT scans. Interestingly, two
recent studies showed that tumor burden measured by PET
could be used to measure the actual tumor burn of
lymphoma [20, 21]. One of these studies showed that active
tumor burden based on PET might be a prognostic indicator
of volumetric response [21]. Volume assessment in these
studies was based on percent reduction in SUVmax. However,
in the present study, we used a volume measurement process
that included a cutoff value of absolute SUV volume
measurement, as described by Freudenberg et al. [17].
PET using the tracer
18F-FDG incorporates metabolic
tumor function with anatomic localization. Tumor volumes
by PET in solid tumors have been associated with clinical
outcome in several studies [22, 23]. However, to the best of
our knowledge, clinical application of tumor burden by PET
as a new staging tool has not yet been reported in DLBCL
patients treated with R-CHOP therapy.
The findings reported in the present study suggest that
total tumor burden of lymphoma is a more important
prognostic parameter than Ann Arbor stage for assessing
DLBCL. In the multivariate analysis, a high MTV had a
greater clinical significance than stage III in survival. This
result demonstrates that the Ann Arbor staging system has
limited use in assessing DLBCL due to the heterogenous
spread pattern of NHL in contrast to HL. Therefore, overall
assessment of tumor burden of lymphoma may be needed
before treatment strategies can be developed. In addition,
the clinical outcome was not different for the patients in the
same MTV state; however, the stage was different. These
results suggest that a simple classification for prognosis
according to diaphragm would not be wise, at least for
DLBCL, in the era of rituximab. The present study was
conducted to analyze the clinical importance of MTV
between only nodal stages II and III DLBCL patients.
Therefore, a further well-designed study including all nodal
stages and extranodal sites is needed.
In conclusion, quantitative assessment of metabolic tumor
volume using PET may potentially be more useful in the
prediction of clinical outcome than the Ann Arbor staging
system in stages II and III of exclusively nodal involved
DLBCL patients treated with R-CHOP.
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